Enfusion, Inc. (NYSE:ENFN) Insider Bronwen Bastone Sells 2,064 Shares

Enfusion, Inc. (NYSE:ENFN) insider Bronwen Bastone sold 2,064 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total transaction of $23,694.72. Following the completion of the sale, the insider now directly owns 225,001 shares in the company, valued at $2,583,011.48. This represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Bronwen Bastone also recently made the following trade(s):

• On Tuesday, January 7th, Bronwen Bastone sold 809 shares of Enfusion stock. The stock was sold at an average price of $10.13, for a total transaction of $8,195.17.

Enfusion Stock Performance

NYSE ENFN opened at $11.45 on Thursday. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of 286.20, a PEG ratio of 1.85 and a beta of 0.96. The company’s 50 day moving average price is $10.95 and its 200 day moving average price is $9.85. Enfusion, Inc. has a one year low of $7.83 and a one year high of $11.80.

Enfusion (NYSE:ENFN) last posted its quarterly earnings data on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The firm had revenue of $52.94 million for the quarter, compared to analysts’ expectations of $53.98 million. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. Sell-side analysts forecast that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Analysts Set New Price Targets

ENFN has been the topic of several research analyst reports. Piper Sandler raised their target price on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. William Blair restated a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Finally, Stifel Nicolaus raised their price target on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $11.13.

Institutional Trading of Enfusion

A number of hedge funds have recently made changes to their positions in the company. Centiva Capital LP raised its stake in shares of Enfusion by 5.0% during the third quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock valued at $243,000 after purchasing an additional 1,227 shares during the period. Harbor Capital Advisors Inc. increased its stake in shares of Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after buying an additional 1,315 shares during the last quarter. Mackenzie Financial Corp increased its stake in shares of Enfusion by 4.8% in the fourth quarter. Mackenzie Financial Corp now owns 31,271 shares of the company’s stock worth $322,000 after buying an additional 1,434 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Enfusion by 5.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,070 shares of the company’s stock worth $289,000 after buying an additional 1,567 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Enfusion by 3.0% in the fourth quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock worth $643,000 after buying an additional 1,796 shares during the last quarter. Hedge funds and other institutional investors own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.